Register



BROWSE BY:

Publications | Publisher | Subjects

Home / Current Pharmaceutical Design, Volume 19, Number 8

Search Ingenta Connect



< previous article

Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe?

Search by

Buy Article: \$68.00 + tax(Refund Policy) **ADD TO CART BUY NOW**

Advanced

Q

Authors: Tomljenovic, Lucija; Pierre Spinosa, Jean; A. Shaw, Christopher

Source: Current Pharmaceutical Design, Volume 19, Number 8, 2013, pp. 1466-1487(22)

next article >

Publisher: Bentham Science Publishers

DOI: https://doi.org/10.2174/138161213804805478

Remember Login ADD TO FAVOURITES

Sign-in -

Username:

Password:

SIGN IN NOW Login reminder Shibboleth OpenAthens


References Citations Abstract Supplementary Data

view table of contents

We carried out a systematic review of HPV vaccine pre- and post-licensure trials to assess the evidence of their effectiveness and safety. We find that HPV vaccine clinical trials design, and data interpretation of both efficacy and safety outcomes, were largely inadequate. Additionally, we note evidence of selective reporting of results from clinical trials (i.e., exclusion of vaccine efficacy figures related to study subgroups in which efficacy might be lower or even negative from peer-reviewed publications). Given this, the widespread optimism regarding HPV vaccines long-term benefits appears to rest on a number of unproven assumptions (or such which are at odd with factual evidence) and significant misinterpretation of available data. For example, the claim that HPV vaccination will result in approximately 70% reduction of cervical cancers is made despite the fact that the clinical trials data have not demonstrated to date that the vaccines have actually prevented a single case of cervical cancer (let alone cervical cancer death), nor that the current overly optimistic surrogate marker-based extrapolations are justified. Likewise, the notion that HPV vaccines have an impressive safety profile is only supported by highly flawed design of safety trials and is contrary to accumulating evidence from vaccine safety surveillance databases and case reports which continue to link HPV vaccination to serious adverse outcomes (including death and permanent disabilities). We thus conclude that further reduction of cervical cancers might be best achieved by optimizing cervical screening (which carries no such risks) and targeting other factors of the disease rather than by the reliance on vaccines with questionable efficacy and safety profiles.

Keywords: Cervarix; Gardasil; HPV vaccines; adverse reactions; cervical cancers; clinical trials; conflict of interests; safety profile; vaccine efficacy; vaccine safety

Document Type: Research Article Publication date: March 1, 2013 More about this publication?





Powered by Google Translate











Access Key

Free content Partial Free content

New content Open access content

🌠 Partial Open access content

Subscribed content

Partial Subscribed content

T Free trial content

Browse by Publication Browse by Subject Browse by Publisher Advanced Search

About us Researchers Librarians

New featured titles Help Contact us









Website © 2023 Ingenta. Article copyright remains with the publisher, society or author(s) as specified within the article.

Ingenta is not the publisher of the publication content on this website. The responsibility for the publication content rests with the publishers providing the material. Please refer to our Terms and Conditions.